Market revenue in 2023 | USD 3,547.3 million |
Market revenue in 2030 | USD 5,992.1 million |
Growth rate | 7.8% (CAGR from 2023 to 2030) |
Largest segment | Liquid delivery device |
Fastest growing segment | Liquid Delivery Device |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Powder delivery device, Liquid Delivery Device, Pressurized Metered Dose Inhaler |
Key market players worldwide | GSK PLC ADR, Teva Pharmaceutical Industries Ltd, AptarGroup Inc, UCB SA, Teleflex Inc, 3M Co, OptiNose Inc, Bespak, Intersect ENT |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intranasal drug and vaccine delivery market will help companies and investors design strategic landscapes.
Liquid delivery device was the largest segment with a revenue share of 44.01% in 2023. Horizon Databook has segmented the China intranasal drug and vaccine delivery market based on powder delivery device, liquid delivery device, pressurized metered dose inhaler covering the revenue growth of each sub-segment from 2018 to 2030.
China accounted for major share of the intranasal drug and vaccine delivery market in Asia Pacific. Factors such as economic growth and increase in the number of local market players in development & manufacturing of novel drug delivery systems are anticipated to drive growth of the intranasal drug and vaccine delivery market in this region.
Healthcare spending in China is significantly increasing and is expected to grow at 8.4% rate annually till 2035. Increasing number of services per case of disease and unit cost are major factors driving this growth by contributing 4.3% and 2.4%, respectively.
This increase in healthcare expenditure is leading to development of advance medical devices in the country. In addition, various preclinical and clinical trials are being conducted in the country by researchers in collaboration with pharmaceutical and biotechnology companies to develop more effective COVID-19 vaccines.
Horizon Databook provides a detailed overview of country-level data and insights on the China intranasal drug and vaccine delivery market , including forecasts for subscribers. This country databook contains high-level insights into China intranasal drug and vaccine delivery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account